The Study of Life Span Reduction and its Causative Diseases in Thorotrast-Administered Patients

托洛司特患者寿命缩短及其病因的研究

• 批准号: 01300006
• 负责人: KAMIYAMA Ryuichi
• 金额: $ 1.28万
• 依托单位: Tokyo Medical and Dental University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Co-operative Research (A)
• 财政年份: 1989
• 资助国家: 日本
• 起止时间: 1989 至 1990
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-01300006/
• 关键词: Thorotrast; Thorium; alpha-ray damage; Radiation late damage; Radiation induced cancer; α線障害; 放射線発癌; 核燃料

1. Epidemiological study : The mortality rate of hepatocellular carcinoma, liver cirrhosis, leukemia, Thorotrast sarcoma, epilepsy, extrahepatic cholangiocarcinoma and malignant peritoneal tumor was significantly higher in Thorotrast-administered patients than in control series. In addition, the high incidence of inflammatory diseases suggests the disturbance of immune system by Thorotrast deposition. Median survival time was decreased in proportion to the injection amounts of Thorotrast.2. Dosimetry : It was estimated that dose rate in alveolar region was about 1 rad/y by concentration of thoron in expiration of Thorotrast-administered patients. It seems that the relationship between the occurrence of lung cancer by high LET radiation and absorbed dose must be further investigated. Thorium content detection method was determined by the neutron activation analysis using tissue samples of Thorotrast-administered patients.3. Clinical study : In Thorotrast-administered patients, the funct … More ion of the reticuloendothelial system, especially phagocytic activity, was depressed and endotoxemia was frequently revealed. The increase of type III collagen in the portal area and sinusoidal wall and type I collagen along the liming plate was observed in Thorotrast liver fibrosis.4. Pathological study : The majority (95.4%) of Thorotrast-related cholangiocarcinoma was located in the middle-peripheral portion of the liver. In contrast, 77.7% of the non-Thorotrast-related cases were located in the hilar region. This prominent difference in tumor location suggests that Thorotrast most likely affects relatively small bile ducts in the periphery or middle portion of the liver. Thorotrast deposition in the spleen was predominantly in the white pulp, marginal zone and in/around the trabecula in the early stage. It is thought that the fibrosis developed from these regions and interconnected each other. In the advanced stage, these spleens became fibrotic shrunken state. Thus, the hypofunction of the spleen such as the increase of erythrocytes having Howell-Jolly bodies appears in these advanced states. In a small number of Thorotrast-administered patients, the cases with splenomegaly were highly complicated by esophageal variceal bleeding as the cause of death. Less

1.流行病学研究：Thorotrast给药患者中肝细胞癌、肝硬化、白血病、Thorotrast肉瘤、癫痫、肝外胆管癌和恶性腹膜肿瘤的死亡率显著高于对照组。此外，炎性疾病的高发病率表明Thorotrast沉积对免疫系统的干扰。中位生存时间随Thorotrat注射量的增加而缩短.剂量测定：根据Thorotrast给药患者呼气中的钍射气浓度，估计肺泡区域的剂量率约为1 rad/y。高LET辐射诱发肺癌与吸收剂量的关系有待进一步研究。使用Thorotrast给药患者的组织样本，通过中子活化分析确定钍含量检测方法.临床研究：在Thorotrast给药患者中， ...更多信息 网状内皮系统的功能，尤其是吞噬功能受到抑制，常出现内毒素血症。Thorotrast肝纤维化大鼠汇管区和肝窦壁III型胶原和沿着灰板I型胶原表达增加.病理学研究：大多数（95.4%）Thorotrast相关胆管癌位于肝脏的中周边部分。相反，77.7%的非Thorotrast相关病例位于肺门区域。肿瘤位置的这种显著差异表明Thorotrast最有可能影响肝脏外围或中部相对较小的胆管。早期Thorotrast在脾脏的沉积主要在白色髓、边缘区和小梁内/周围。据认为，纤维化是从这些区域发展起来的，并且相互连接。晚期脾脏呈纤维化萎缩状态。因此，脾功能减退，例如具有Howell-Jolly小体的红细胞增加，出现在这些晚期状态中。在少数Thorotrast给药患者中，脾肿大病例高度并发食管静脉曲张出血，这是死亡原因。少

项目成果

入江 宏 ほか: "トロトラスト肝硬変症の臨床・病理学的特徴" 医学のあゆみ. 149. 581-582 (1989)

Hiroshi Irie 等：“trotrast 肝硬化的临床和病理特征”，《医学史》149. 581-582 (1989)。

Iwata,S.et al.: "possibility of radon as a causative agent of lung cancer" Annu.Rep.Res.Reactor Inst.,Kyoto Univ.23. 149-153 (1990)

Iwata,S.et al.：“氡作为肺癌致病因子的可能性”Annu.Rep.Res.Reactor Inst.，Kyoto Univ.23。

Ishikawa, Y. et al.: "Late effects of alpha-particles on Thorotrast patients in Japan." British Institute of Radiology Report. 21. 129-131 (1989)

Ishikawa, Y. 等人：“α 粒子对日本 Thorotrast 患者的后期影响。”

Sugiyama, H. et al.: "Clinical observations on the Japanese Thorotrast patients : measurement of liver and spleen volume by computerized tomography." British Institute of Radiology Report. 21. 136-137 (1989)

Sugiyama, H. 等人：“日本胸腔穿刺术患者的临床观察：通过计算机断层扫描测量肝脏和脾脏体积。”

入江 宏ほか: "トロトラスト被注入者剖検例にみられる脾臓の変化とくに門脈圧亢進との関係について" 医学のあゆみ. 156. 427-428 (1991)

Hiroshi Irie 等人：“在注射 Thorotrast 的患者尸检病例中观察到的脾脏变化，特别是它们与门脉高压的关系”，《医学史》156. 427-428 (1991)。